CLS.TO · TOR · Technology
Celestica Inc.
Also onConsensus Drift
Implied value per share
CAD 155.60
Market price
CAD 465.13
Implied upside
-66.5%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case · USD model at 1.3982
Current EV/EBITDA of 47.2x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 14.8bn | USD 17.7bn | USD 21.2bn | USD 25.3bn | USD 30.3bn | +19.6% |
| EBIT | USD 871.7m | USD 1.0bn | USD 1.2bn | USD 1.5bn | USD 1.8bn | +19.6% |
| NOPAT | USD 698.6m | USD 835.3m | USD 998.7m | USD 1.2bn | USD 1.4bn | +19.6% |
| Add depreciation & amortisation | USD 230.9m | USD 276.1m | USD 330.1m | USD 394.6m | USD 471.8m | +19.6% |
| Less capital expenditure | USD -239.6m | USD -286.5m | USD -342.6m | USD -409.6m | USD -489.7m | +19.6% |
| Less increase in working capital | USD -101.7m | USD -121.6m | USD -145.4m | USD -173.8m | USD -207.8m | +19.6% |
| Free cashflow to firm | USD 588.2m | USD 703.3m | USD 840.8m | USD 1.0bn | USD 1.2bn | +19.6% |
| Discount factor | 0.9516 | 0.8616 | 0.7801 | 0.7064 | 0.6396 | - |
| Present value | USD 559.7m | USD 605.9m | USD 655.9m | USD 710.1m | USD 768.7m | +8.3% |
| Present Value Of The Forecast | USD 3.3bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 3.30% | CAD assumption - no free live source available for this market (assumption) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 1.311 | Reported 1.464, pulled toward 1.0 (Blume) |
| Cost of equity | 10.51% | Risk-free + beta x equity risk premium |
| Cost of debt | 6.69% | Interest expense / average total debt |
| Market capitalisation | USD 58.7bn | 98.7% of capital |
| Total debt | USD 776.5m | 1.3% of capital, book value as a proxy |
| Tax rate | 19.9% | Effective, capped at statutory |
| WACC | 10.44% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
75% of EV
- Forecast FCFF, final year
- USD 1.2bn
- Capex at depreciation, working capital in reinvestment
- USD 1.4bn
- Less reinvestment at g/ROIC (16.7% of NOPAT)
- USD -238.8m
- Capitalised
- USD 1.2bn
- ROIC (reported)
- 14.9%
- Terminal value, undiscounted
- USD 15.3bn
- Terminal value, discounted
- USD 9.8bn
- Enterprise value
- USD 13.1bn
- Less net debt
- USD 180.9m
- Equity value
- USD 12.9bn
Exit at 20.0x EBITDA
90% of EV
- Terminal value, undiscounted
- USD 45.1bn
- Terminal value, discounted
- USD 28.8bn
- Enterprise value
- USD 32.1bn
- Less net debt
- USD 180.9m
- Equity value
- USD 31.9bn
Spread between methods: 85%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 8.44% | 140.48 | 145.26 | 150.81 | 157.32 | 165.09 |
| 9.44% | 121.66 | 124.72 | 128.19 | 132.15 | 136.73 |
| 10.44% | 107.08 | 109.08 | 111.29 | 113.77 | 116.56 |
| 11.44% | 95.47 | 96.78 | 98.20 | 99.75 | 101.48 |
| 12.44% | 86.02 | 86.86 | 87.76 | 88.73 | 89.78 |
Outlined: this model. Green text: above today's price of 332.66. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 19.6% | 52.2% | +32.6pp |
| EBIT margin | 5.9% | 16.9% | +11.0pp |
| Discount rate | 10.4% | 5.3% | -5.2pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.